Browse the evidence

Early Time-Restricted Eating (eTRE) with an 8-hour window (8 am - 4 pm) does NOT produce significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Early time-restricted eating (8 am - 4 pm) with a 600-calorie deficit did not result in significantly greater weight loss than a standard Mediterranean diet in this study. You may not see extra benefits from this specific timing strategy.

Chronic low-grade inflammation, driven by obesity and ectopic lipid deposition, impairs insulin signaling and beta-cell function through pathways like NF-κB, JNK, and oxidative stress.

Inflammation is not just a symptom of diabetes; it is a cause. Excess fat, especially around organs (ectopic fat), triggers inflammation that blocks insulin from working and damages insulin-producing cells. Managing weight and diet reduces this inflammation.

Global dietary quality, measured by the Alternative Healthy Eating Index (AHEI), is modest (mean score 40.3/100) and has improved only slightly (+1.5 points) globally between 1990 and 2018, with significant regional disparities where South Asia and Sub-Saharan Africa saw no improvement or decline.

Your overall diet matters more than any single food. Globally, average diet quality is low (40/100). To improve, focus on increasing fruits, vegetables, whole grains, and healthy fats while reducing sugar-sweetened beverages, red/processed meat, and sodium. This applies to everyone, but the specific gaps vary by region and education level. In many areas, simply increasing produce intake yields the biggest health return.

GIP promotes lipogenesis (fat storage) in adipose tissue, while GLP-1 promotes lipolysis (fat breakdown) indirectly via sympathetic nervous system activation.

GIP helps store fat in adipose tissue, while GLP-1 helps break it down. Dual agonists balance these effects to improve overall metabolic health.

Menstrual cycle phase does not appreciably influence acute strength performance or chronic adaptations (strength/hypertrophy) to resistance exercise training in naturally cycling women.

Do not restrict your training volume, intensity, or frequency based on your menstrual cycle phase. The current scientific consensus indicates that hormonal fluctuations across the cycle do not significantly impact your ability to build strength or muscle. Focus on consistent, high-quality resistance training regardless of where you are in your cycle. If you experience menstrual symptoms that affect your well-being, adjust for comfort, not for perceived biological incapacity.

Weight stigma and discrimination are significant behavioral and emotional mechanisms linking high body weight to psychological distress.

Recognize that weight stigma is a real and harmful social force, not a personal failing. Seek supportive environments and mental health resources that address the impact of discrimination.

Systemic inflammation and HPA-axis dysregulation are biological mechanisms mediating the link between high body weight and psychological distress.

Understand that biological factors like inflammation and stress hormone dysregulation contribute to the link between obesity and depression. This is not just 'in your head' but has a physical basis.

Global sugar-sweetened beverage (SSB) intake among adults increased by 16% (0.37 servings/week) between 1990 and 2018, with the most dramatic increases occurring in Sub-Saharan Africa (+81.9%) and specific high-population countries like Nigeria and Ethiopia.

Track your weekly SSB servings. If you live in or travel to regions with rapidly rising intake (like Sub-Saharan Africa or parts of Asia), be aware that marketing is aggressively targeting these demographics. Aim to keep added sugars <5-10% of daily calories as recommended by national guidelines.

High-fat diets (>46% calories from fat, <21% from carbs) do not improve exercise performance despite increasing fat oxidation.

Do not follow a high-fat, low-carb diet to improve performance. While it may help your body burn more fat, it does not make you faster and can actually hurt your performance, especially in intense or long events.

GLP-1 receptor agonists (specifically liraglutide and dulaglutide) are associated with a statistically significant increase in the risk of overall thyroid disorders compared to placebo or other interventions, although they do not significantly increase the risk of specific conditions like thyroid cancer, hyperthyroidism, or hypothyroidism.

If you are taking a GLP-1 medication like liraglutide or dulaglutide, be aware that there is a slightly higher statistical risk of developing 'overall thyroid disorders' compared to those not taking the drug. However, this does not appear to increase your risk of thyroid cancer or major thyroid dysfunction. Standard monitoring is advised, but the fear of cancer based on animal studies is not supported by large human clinical trials.

Among specific GLP-1 receptor agonists, liraglutide and dulaglutide show a statistically significant increase in the risk of overall thyroid disorders, whereas semaglutide, lixisenatide, and exenatide do not show a significant effect.

Not all GLP-1 medications affect the thyroid equally. If you are concerned about thyroid health, liraglutide and dulaglutide have shown a statistically significant increase in overall thyroid disorders in large trials, whereas semaglutide, lixisenatide, and exenatide have not shown this significant risk. Discuss these differences with your provider when choosing a specific agent.

Tirzepatide requires GIP receptor (GIPR) activation to stimulate insulin secretion in human islets, as blocking GIPR consistently reduces this response.

Tirzepatide's effectiveness in lowering blood sugar relies on its ability to activate the GIP receptor, not just the GLP-1 receptor. In human tissue, blocking the GIP receptor stops tirzepatide from stimulating insulin, proving this second pathway is essential for its full benefit.

Tirzepatide stimulates glucagon secretion in human islets primarily through GIP receptor activation, which overrides the glucagon-suppressing effect of GLP-1 receptor activation.

Tirzepatide increases glucagon secretion via the GIP receptor, which might seem counterintuitive for a diabetes drug. However, this is a normal physiological response to nutrient sensing, and the drug's overall effect is still a significant reduction in blood glucose due to its powerful insulin-stimulating effects.

Tirzepatide stimulates insulin secretion in mouse islets predominantly through the GLP-1 receptor, with minimal GIP receptor contribution at therapeutic doses.

Research on tirzepatide using mice may not fully reflect how it works in humans, as mice require much higher doses for GIP receptor activation. This highlights the importance of human-specific studies for understanding the drug's full mechanism.

Treatment with GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) is associated with a significantly increased risk of developing psychiatric disorders, including major depression, anxiety, and suicidal behavior, in patients with obesity.

If you are taking or considering GLP-1 medications like Ozempic or Wegovy for obesity, be aware that studies link these drugs to a higher risk of depression, anxiety, and suicidal thoughts, especially with long-term use. Discuss your mental health history with your doctor before starting, and monitor your mood closely. If you experience worsening depression or suicidal thoughts, contact your healthcare provider immediately.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with increased subclinical atherosclerosis (measured by carotid intima-media thickness and coronary artery calcification) and incident cardiovascular events, but does not independently increase cardiovascular mortality risk after adjusting for confounders.

If you have MASLD, prioritize cardiovascular risk management (blood pressure, lipids, glucose) as aggressively as you manage your liver health. Your risk of heart events is elevated, but your risk of dying from liver failure is lower than dying from heart disease. Comprehensive cardiometabolic risk management is warranted.

GLP-1 receptor agonists do not significantly increase energy expenditure in humans, despite evidence in animal models.

Don't expect GLP-1 drugs to burn extra calories at rest. They work by reducing food intake.

Enteroendocrine cells (EECs) regulate the gut-brain axis through two distinct mechanisms: slow endocrine hormone release into the bloodstream and rapid synaptic signaling via neuropod cells.

Your gut has a direct 'phone line' to your brain. Foods trigger specific cells (EECs) that send signals either slowly through hormones or instantly through nerves. This is why drugs like semaglutide (Ozempic) work—they amplify these natural signals to regulate hunger and blood sugar. Understanding this helps explain why gut health directly impacts mood and metabolism.

Neuropod cells communicate nutrient information to the vagus nerve primarily via glutamate release, allowing for rapid distinction between sugar and artificial sweeteners.

Your gut has a specific 'sugar detector' (neuropod cells) that sends a fast signal to your brain using glutamate. This signal is triggered by real sugar (sucrose) but not by artificial sweeteners. This might explain why artificial sweeteners don't always satisfy sugar cravings or trigger the same metabolic responses as real sugar.

Serotonin (5-HT) released from enterochromaffin (EC) cells modulates visceral sensitivity and pain signaling via direct synaptic interaction with nociceptive neurons.

If you have IBS or chronic gut pain, your gut cells (EC cells) might be sending too many pain signals to your brain using serotonin. Blocking these signals (with specific antagonists) can reduce pain and anxiety, showing that gut pain is a neurological issue, not just inflammation.

No country globally achieves the combined WHO target of potassium intake >3.5 g/day and sodium intake <2 g/day.

It is currently impossible to meet both sodium and potassium guidelines simultaneously in most countries. Focus on reducing discretionary salt intake and increasing potassium-rich foods like fruits and vegetables, as this is the most feasible path to improving cardiovascular health.

Tirzepatide treatment is not significantly associated with an increased risk of pancreatitis compared to control groups (placebo, basal insulin, or GLP-1 RAs) in patients with type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity and are considering Tirzepatide, current data from multiple clinical trials suggests it does not significantly increase your risk of pancreatitis compared to other common diabetes or weight-loss medications. This is reassuring news if you were avoiding the drug due to fears of pancreatic inflammation.

Tirzepatide is associated with a significantly increased risk of composite gallbladder or biliary diseases (including cholelithiasis, cholecystitis, and other gallbladder disorders) compared to placebo or basal insulin, but not compared to GLP-1 RAs.

Tirzepatide increases the risk of gallbladder or biliary issues (like gallstones or inflammation) compared to placebos or insulin. However, this risk appears similar to other GLP-1 medications. Be aware of symptoms like abdominal pain and report them to your doctor promptly, as early detection is key.

Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.